A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects
TQF3250 capsule is a biased GLP-1 (glucagon-like peptide-1) receptor agonist developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. By binding to the GLP-1 receptor, it can selectively activate certain signaling pathways of the GLP-1 receptor and reduce activation of other pathways, thereby bringing higher effic
| Condition(s) | Hyperglycemia |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | TQF3250 capsule is a biased GLP-1 (glucagon-like peptide-1) receptor agonist developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. By binding to the GLP-1 receptor, it can selectively activate certain signaling pathways of the GLP-1 receptor and reduce activation of other pathways, thereby bringing higher efficacy and lower side effects. |
| Who can participate | Inclusion Criteria: * Chinese subjects aged above 18 years old (including 18 years old) and below 55 years old (including 55 years old); * Those who voluntarily sign a written informed consent form before the trial, have a full understanding of the trial content, process and possible adverse reactions, can communicate well with the researcher, and understand and comply with the requirements of this study; * Women of childbearing potential should agree to use effective contraceptive measures during the study and for 6 months after the end of the study; * Male weight ≥50 kg, female weight ≥45 kg, body mass index (BMI) between 20-40kg/m2 (including both ends of the cutoff); Exclusion Criteria: * Pregnant and lactating women. * Those whose vital signs, physical examination, laboratory examinat |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Lead sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Locations | Nanjing, Jiangsu, China |
| Start date | 2025-12-18 |
| NCT ID | NCT07327281 |
| Official listing | https://clinicaltrials.gov/study/NCT07327281 |